--A Fresenius SE & Co. executive has said his company experienced testing problems similar to those that Fresenius cited as grounds for pulling out of a $4.3 billion deal to buy U.S. generic-drug maker Akorn Inc., Bloomberg reports.

--Mats Henriksson testified on Thursday in Delaware that it took Fresenius two years to address questions raised by the U.S. Food and Drug Administration in 2013 regarding drug-injection testing and test-result storage at a Fresenius plant in India, Bloomberg said.

 

Full story: https://bloom.bg/2Jj178B

 

Write to Barcelona editors at barcelonaeditors@dowjones.com

 

(END) Dow Jones Newswires

July 13, 2018 05:16 ET (09:16 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Akorn (NASDAQ:AKRX)
Historical Stock Chart
Von Feb 2024 bis Mär 2024 Click Here for more Akorn Charts.
Akorn (NASDAQ:AKRX)
Historical Stock Chart
Von Mär 2023 bis Mär 2024 Click Here for more Akorn Charts.